You are now leaving Mitsubishi Tanabe Pharma Canada and visiting a third-party website.

If you are interested in exploring careers at MTP-CA, please email
contact@mt-pharma-canada.com.

Media Center

Background Image

Press Releases

  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) has been added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces that Company’s Treatment for Amyotrophic Lateral Sclerosis (ALS) has been added to the Provincial Drug Plan in Quebec

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Concludes Letter of Intent with Pan-Canadian Pharmaceutical Alliance for RADICAVA® (edaravone)

    TORONTO, April 22, 2020 - Mitsubishi...

    Read More
  • MTP-CA’s Response to COVID-19

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More
  • Mitsubishi Tanabe Pharma Canada Announces Availability of RADICAVA® (edaravone) for Amyotrophic Lateral Sclerosis

    Mitsubishi Tanabe Pharma Canada, Inc....

    Read More